SQM (NYSE: SQM) to double Mt Holland lithium output with expansion
SQM and Wesfarmers announced a final investment decision to expand the Mt Holland lithium project via their Covalent Lithium JV. The expansion will add a second concentrator and new ore sorting, doubling spodumene concentrate output to about 760,000 tonnes per year from ~380,000. SQM’s capex share is estimated at US$450 million to US$500 million, with first production expected in 1H 2030.
How this was made
The 30-second read
Why it matters
The company discloses a definitive feasibility study outcome, a production doubling target, a capex range, and a staged timeline (construction in 2H 2027, first expanded production in H1 2030), which can change investor expectations for future lithium output and costs.
Market read
Traders can update SQM’s lithium growth and cost expectations based on the disclosed doubling plan, capex range, and production ramp schedule.
What to watch
The project estimate excludes life-of-mine capital expenditure, and approvals are “secured or underway,” leaving residual regulatory/execution risk before construction begins.
Background
SQM’s Mt Holland lithium project is operated via Covalent Lithium, a joint venture with Wesfarmers; this filing reports the joint final investment decision to expand capacity.
Ticker impact
SQM and Wesfarmers approved a final investment decision to expand Mt Holland, doubling spodumene concentrate output to 760,000 tpy.
Near-term: modest positive bias on growth/cost narrative. Medium-term: follow-through depends on lithium pricing and execution risk for 2027-2030 ramp.
The filing provides specific production increase, capex range ($450m-$500m), and first production timing (H1 2030), which can re-rate SQM’s lithium segment expectations, but it is not an immediate earnings print.
Market effects
Reinforces the theme of incremental lithium supply additions and potential cost-curve pressure if execution delivers lower unit operating costs.
Chile-linked lithium producer capex signals continued investment in South American lithium supply chains.
Mt Holland expansion affects global spodumene concentrate availability and could influence benchmark pricing expectations over the 2027-2030 window.
Counterpoint
Doubling capacity may not translate into value if lithium prices weaken or if unit cost benefits fail to materialize during ramp-up.
Key entities
- public_companySQM
Sociedad Química y Minera de Chile S.A., the NYSE-listed lithium producer filing the Form 6-K.
- public_companyWesfarmers
Joint venture partner (ASX: WES) in Covalent Lithium for the Mt Holland expansion.
- joint_ventureCovalent Lithium
JV company owned by SQM and Wesfarmers that completed the definitive feasibility study and will execute the expansion.
- projectMt Holland lithium project
Mine and concentrator expansion plus new integrated ore sorting facility, targeting 760,000 tpy spodumene concentrate.
